cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.4643646
title: Dataset from Biagioli V, Belloni S, Albanesi B, Piredda A, Caruso R. Comment on "The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region" and reflections from the Italian Association of Oncology Nurses. Eur J Cancer. 2020 Aug;135:8-10. doi: 10.1016/j.ejca.2020.05.022. Epub 2020 Jun 4. PMID: 32521294; PMCID: PMC7269936.

description: Dataset from the Letter to the Editor Biagioli V, Belloni S, Albanesi B, Piredda A, Caruso R. Comment on "The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region" and reflections from the Italian Association of Oncology Nurses. Eur J Cancer. 2020 Aug;135:8-10. doi: 10.1016/j.ejca.2020.05.022. Epub 2020 Jun 4. PMID: 32521294; PMCID: PMC7269936.
DOI: 10.15129/ea954936-8a0b-46c0-b8b2-dbd7ced430f3
title: Data for: "Potential of Low-Voltage Organic Transistors with High On-State Drain Current for Temperature Sensor Development"

description: This dataset is associated with a paper titled "Potential of Low-Voltage Organic Transistors with High On-State Drain Current for Temperature Sensor Development" published in Organic Electronics on March 26, 2021, https://doi.org/10.1016/j.orgel.2021.106152. All experimental details are thoroughly described in the paper. All data are placed in one Excel file (version 2016) and are fully self-explanatory.
DOI: 10.15128/r1k643b122q
title: Bioinspired and Eco-Friendly High Efficacy Cinnamaldehyde Antibacterial Surfaces [dataset]

description: Antimicrobial essential oils are incorporated into mussel-inspired and natural plant polyphenol coatings as part of a single-step fabrication process. Polydopamine–cinnamaldehyde, polyethyleneimine–cinnamaldehyde, and tannic acid–cinnamaldehyde coatings exhibit strong antibacterial activities against both Gram-negative Escherichia coli and Gram-positive Staphylococcus aureus (with the polydopamine- and tannic acid-based systems displaying log10 Reduction = 8). Cinnamaldehyde impregnation into porous non-woven polypropylene cloth, polytetrafluoroethylene membrane, and knitted cotton cloth also gives rise to high levels of antibacterial activity (log10 Reduction = 8). No loss in antibacterial efficacy is observed for non-woven polypropylene cloth impregnated with cinnamaldehyde over 17 recycle tests.
DOI: 10.5281/zenodo.4630975
title: Data set related to the article "The longevity-associated variant of BPIFB4 improves a CXCR4-mediated striatum-microglia crosstalk preventing disease progression in a mouse model of Huntington's disease"

description: This record contains raw data related to the article "The longevity-associated variant of BPIFB4 improves a CXCR4-mediated striatum-microglia crosstalk preventing disease progression in a mouse model of Huntington's disease". The longevity-associated variant (LAV) of the bactericidal/permeability-increasing fold-containing family B member 4 (BPIFB4) has been found significantly enriched in long-living individuals. Neuroinflammation is a key player in Huntington's disease (HD), a neurodegenerative disorder caused by neural death due to expanded CAG repeats encoding a long polyglutamine tract in the huntingtin protein (Htt). Herein, we showed that striatal-derived cell lines with expanded Htt (STHdh Q<sup>111/111</sup>) expressed and secreted lower levels of BPIFB4, when compared with Htt expressing cells (STHdh Q<sup>7/7</sup>), which correlated with a defective stress response to proteasome inhibition. Overexpression of LAV-BPIFB4 in STHdh Q<sup>111/111</sup> cells was able to rescue both the BPIFB4 secretory profile and the proliferative/survival response. According to a well-established immunomodulatory role of LAV-BPIFB4, conditioned media from LAV-BPIFB4-overexpressing STHdh Q111<sup>/111</sup> cells were able to educate Immortalized Human Microglia-SV40 microglial cells. While STHdh Q<sup>111/111</sup> dying cells were ineffective to induce a CD163 + IL-10<sup>high</sup> pro-resolving microglia compared to normal STHdh Q<sup>7/7</sup>, LAV-BPIFB4 transduction promptly restored the central immune control through a mechanism involving the stromal cell-derived factor-1. In line with the in vitro results, adeno-associated viral-mediated administration of LAV-BPIFB4 exerted a CXCR4-dependent neuroprotective action in vivo in the R6/2 HD mouse model by preventing important hallmarks of the disease including motor dysfunction, body weight loss, and mutant huntingtin protein aggregation. In this view, LAV-BPIFB4, due to its pleiotropic ability in both immune compartment and cellular homeostasis, may represent a candidate for developing new treatment for HD.
DOI: 10.5281/zenodo.4630679
title: Data set related to the article "The longevity-associated variant of BPIFB4 improves a CXCR4-mediated striatum-microglia crosstalk preventing disease progression in a mouse model of Huntington's disease"

description: This record contains raw data related to the article "The longevity-associated variant of BPIFB4 improves a CXCR4-mediated striatum-microglia crosstalk preventing disease progression in a mouse model of Huntington's disease". The longevity-associated variant (LAV) of the bactericidal/permeability-increasing fold-containing family B member 4 (BPIFB4) has been found significantly enriched in long-living individuals. Neuroinflammation is a key player in Huntington's disease (HD), a neurodegenerative disorder caused by neural death due to expanded CAG repeats encoding a long polyglutamine tract in the huntingtin protein (Htt). Herein, we showed that striatal-derived cell lines with expanded Htt (STHdh Q<sup>111/111</sup>) expressed and secreted lower levels of BPIFB4, when compared with Htt expressing cells (STHdh Q<sup>7/7</sup>), which correlated with a defective stress response to proteasome inhibition. Overexpression of LAV-BPIFB4 in STHdh Q<sup>111/111</sup> cells was able to rescue both the BPIFB4 secretory profile and the proliferative/survival response. According to a well-established immunomodulatory role of LAV-BPIFB4, conditioned media from LAV-BPIFB4-overexpressing STHdh Q111<sup>/111</sup> cells were able to educate Immortalized Human Microglia-SV40 microglial cells. While STHdh Q<sup>111/111</sup> dying cells were ineffective to induce a CD163 + IL-10<sup>high</sup> pro-resolving microglia compared to normal STHdh Q<sup>7/7</sup>, LAV-BPIFB4 transduction promptly restored the central immune control through a mechanism involving the stromal cell-derived factor-1. In line with the in vitro results, adeno-associated viral-mediated administration of LAV-BPIFB4 exerted a CXCR4-dependent neuroprotective action in vivo in the R6/2 HD mouse model by preventing important hallmarks of the disease including motor dysfunction, body weight loss, and mutant huntingtin protein aggregation. In this view, LAV-BPIFB4, due to its pleiotropic ability in both immune compartment and cellular homeostasis, may represent a candidate for developing new treatment for HD.
DOI: 10.5281/zenodo.4616624
title: Data set related to the article "Transfer of a human gene variant associated with exceptional longevity improves cardiac function in obese type 2 diabetic mice through induction of the SDF-1/CXCR4 signaling pathway"

description: This record contains raw data related to the article ""Transfer of a human gene variant associated with exceptional longevity improves cardiac function in obese type 2 diabetic mice through induction of the SDF-1/CXCR4 signaling pathway". <strong>Abstract</strong> <strong>Aims: </strong>Homozygosity for a four-missense single-nucleotide polymorphism haplotype of the human BPIFB4 gene is enriched in long-living individuals. Delivery of this longevity-associated variant (LAV) improved revascularisation and reduced endothelial dysfunction and atherosclerosis in mice through a mechanism involving the stromal cell-derived factor-1 (SDF-1). Here, we investigated if delivery of the LAV-BPIFB4 gene may attenuate the progression of diabetic cardiomyopathy. <strong>Methods and results: </strong>Compared with age-matched lean controls, diabetic db/db mice showed altered echocardiographic indices of diastolic and systolic function and histological evidence of microvascular rarefaction, lipid accumulation, and fibrosis in the myocardium. All these alterations, as well as endothelial dysfunction, were prevented by systemic LAV-BPIFB4 gene therapy using an adeno-associated viral vector serotype 9 (AAV9). In contrast, AAV9 wild-type-BPIFB4 exerted no benefit. Interestingly, LAV-BPIFB4-treated mice showed increased SDF-1 levels in peripheral blood and myocardium and up-regulation of the cardiac myosin heavy chain isoform alpha, a contractile protein that was reduced in diabetic hearts. SDF-1 up-regulation was instrumental to LAV-BPIFB4-induced benefit as both haemodynamic and structural improvements were inhibited by an orally active antagonist of the SDF-1 CXCR4 receptor. <strong>Conclusions: </strong>In mice with type-2 diabetes, LAV-BPIFB4 gene therapy promotes an advantageous remodelling of the heart, allowing it to better withstand diabetes-induced stress. These results support the viability of transferring healthy characteristics of longevity to attenuate diabetic cardiac disease.
DOI: 10.5281/zenodo.4616623
title: Data set related to the article "Transfer of a human gene variant associated with exceptional longevity improves cardiac function in obese type 2 diabetic mice through induction of the SDF-1/CXCR4 signaling pathway"

description: This record contains raw data related to the article ""Transfer of a human gene variant associated with exceptional longevity improves cardiac function in obese type 2 diabetic mice through induction of the SDF-1/CXCR4 signaling pathway". <strong>Abstract</strong> <strong>Aims: </strong>Homozygosity for a four-missense single-nucleotide polymorphism haplotype of the human BPIFB4 gene is enriched in long-living individuals. Delivery of this longevity-associated variant (LAV) improved revascularisation and reduced endothelial dysfunction and atherosclerosis in mice through a mechanism involving the stromal cell-derived factor-1 (SDF-1). Here, we investigated if delivery of the LAV-BPIFB4 gene may attenuate the progression of diabetic cardiomyopathy. <strong>Methods and results: </strong>Compared with age-matched lean controls, diabetic db/db mice showed altered echocardiographic indices of diastolic and systolic function and histological evidence of microvascular rarefaction, lipid accumulation, and fibrosis in the myocardium. All these alterations, as well as endothelial dysfunction, were prevented by systemic LAV-BPIFB4 gene therapy using an adeno-associated viral vector serotype 9 (AAV9). In contrast, AAV9 wild-type-BPIFB4 exerted no benefit. Interestingly, LAV-BPIFB4-treated mice showed increased SDF-1 levels in peripheral blood and myocardium and up-regulation of the cardiac myosin heavy chain isoform alpha, a contractile protein that was reduced in diabetic hearts. SDF-1 up-regulation was instrumental to LAV-BPIFB4-induced benefit as both haemodynamic and structural improvements were inhibited by an orally active antagonist of the SDF-1 CXCR4 receptor. <strong>Conclusions: </strong>In mice with type-2 diabetes, LAV-BPIFB4 gene therapy promotes an advantageous remodelling of the heart, allowing it to better withstand diabetes-induced stress. These results support the viability of transferring healthy characteristics of longevity to attenuate diabetic cardiac disease.
DOI: 10.6084/m9.figshare.14332898
title: Supplementary Material for: Efficacy and Safety of Sacubitril/Valsartan Therapy for Acute Decompensated Heart Failure with Reduced Ejection Fraction during the Vulnerable Phase: A Multicenter, Assessor-Blinded, Prospective, Observational, Cohort Study

description: <b><i>Background:</i></b> The 3-month period after hospitalization for acute cardiac failure is a vulnerable phase with the highest risk of mortality and rehospitalization. Safety and efficacy of early initiation of sacubitril/valsartan during the index hospitalization for acute decompensated heart failure (ADHF) is unclear. Therefore, we tested whether sacubitril/valsartan could result in a lower rate of a composite outcome of first hospitalization for heart failure and death from cardiovascular causes compared to inhibition of the renin-angiotensin system alone. <b><i>Methods:</i></b> We enrolled patients hospitalized for ADHF and reduced ejection fraction at 4 sites; patients were divided into a sacubitril/valsartan group or an angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) group. All patients were followed up for 3 months after discharge. The primary endpoint was outcomes as a composite of death from cardiovascular causes and rehospitalization for heart failure. <b><i>Results:</i></b> In total, 251 patients who received sacubitril/valsartan and 251 patients who received ACEIs/ARBs had similar propensity scores and were included and compared. The primary endpoint was reached in 40 patients (15.9%) treated with sacubitril/valsartan and in 59 patients (23.5%) managed by ACEI/ARB (HR, 0.650; 95% CI: 0.435–0.971; <i>p</i> = 0.035). The NYHA class improved in 72.1% of patients in the sacubitril/valsartan group and in 59.8% of patients in the ACEI/ARB group (HR, 1.303; 95% CI: 1.097–1.548, <i>p</i> = 0.004). The key safety outcomes endpoints did not significantly differ. <b><i>Conclusions:</i></b> Among patients hospitalized with ADHF and reduced left ventricular ejection fraction, we observed that sacubitril/valsartan therapy led to reduction in death from cardiovascular causes and rehospitalizations for heart failure when compared to ACEI/ARB therapy alone during the vulnerable phase. Our results support that sacubitril/valsartan may be administered early in the vulnerable phase after ADHF and improves NYHA class.
DOI: 10.5281/zenodo.4643377
title: Dataset related to article "BENEFIT: real-world effectiveness of SB4 after transition from reference etanercept in rheumatoid arthritis and axial spondyloarthritis"

description: This record contains data related to the article "BENEFIT: real-world effectiveness of SB4 after transition from reference etanercept in rheumatoid arthritis and axial spondyloarthritis". <strong>Objectives: </strong> The objective of this non-interventional study was to evaluate the effectiveness and safety of the etanercept biosimilar SB4 (BenepaliTM) following transition from reference etanercept in patients with rheumatoid arthritis (RA) or axial spondyloarthritis (axSpA). <strong>Methods: </strong> Data were collected from clinical records of adult patients with stable RA or axSpA, in France, Germany, Italy and Spain. Key outcomes included the change from transition to 3 and 6 months in Disease Activity Score 28 (DAS28) for RA or Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for axSpA. <strong>Results: </strong> In total, 358 patients with RA and 199 patients with axSpA were enrolled. The mean individual change in disease score from transition was -0.02 (95% confidence interval [CI] -0.11, 0.08) at 3 months and 0.01 (95% CI -0.09, 0.11) at 6 months for DAS28, and -0.01 (95% CI -0.24, 0.21) at 3 months and -0.11 (95% CI -0.31, 0.10) at 6 months for BASDAI. In the RA cohort, 19 (5.3%) and 5 patients (1.4%) reported adverse events and serious adverse events (SAEs), respectively. In the axSpA cohort, 12 (6.0%) and 2 patients (1.0%) reported adverse events and SAEs, respectively. One SAE of pneumonia (RA cohort) was considered to be related to SB4 administration. At 6 months post-transition, the SB4 retention rate was 90.8% (95% CI 87.2%, 93.4%) in the RA cohort and 92.4% (95% CI 87.5%, 95.4%) in the axSpA cohort. <strong>Conclusions: </strong> Transition from reference etanercept to SB4 is effective and safe in patients with stable RA and axSpA.
DOI: 10.5281/zenodo.4643376
title: Dataset related to article "BENEFIT: real-world effectiveness of SB4 after transition from reference etanercept in rheumatoid arthritis and axial spondyloarthritis"

description: This record contains data related to the article "BENEFIT: real-world effectiveness of SB4 after transition from reference etanercept in rheumatoid arthritis and axial spondyloarthritis". <strong>Objectives: </strong> The objective of this non-interventional study was to evaluate the effectiveness and safety of the etanercept biosimilar SB4 (BenepaliTM) following transition from reference etanercept in patients with rheumatoid arthritis (RA) or axial spondyloarthritis (axSpA). <strong>Methods: </strong> Data were collected from clinical records of adult patients with stable RA or axSpA, in France, Germany, Italy and Spain. Key outcomes included the change from transition to 3 and 6 months in Disease Activity Score 28 (DAS28) for RA or Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for axSpA. <strong>Results: </strong> In total, 358 patients with RA and 199 patients with axSpA were enrolled. The mean individual change in disease score from transition was -0.02 (95% confidence interval [CI] -0.11, 0.08) at 3 months and 0.01 (95% CI -0.09, 0.11) at 6 months for DAS28, and -0.01 (95% CI -0.24, 0.21) at 3 months and -0.11 (95% CI -0.31, 0.10) at 6 months for BASDAI. In the RA cohort, 19 (5.3%) and 5 patients (1.4%) reported adverse events and serious adverse events (SAEs), respectively. In the axSpA cohort, 12 (6.0%) and 2 patients (1.0%) reported adverse events and SAEs, respectively. One SAE of pneumonia (RA cohort) was considered to be related to SB4 administration. At 6 months post-transition, the SB4 retention rate was 90.8% (95% CI 87.2%, 93.4%) in the RA cohort and 92.4% (95% CI 87.5%, 95.4%) in the axSpA cohort. <strong>Conclusions: </strong> Transition from reference etanercept to SB4 is effective and safe in patients with stable RA and axSpA.
DOI: 10.5281/zenodo.4643707
title: Dataset from Biagioli V, Albanesi B, Belloni S, Piredda A, Caruso R. Living with cancer in the COVID-19 pandemic: An Italian survey on self-isolation at home. Eur J Cancer Care (Engl). 2021 Mar;30(2):e13385. doi: 10.1111/ecc.13385. Epub 2020 Dec 7. PMID: 33289205; PMCID: PMC7883078.

description: Dataset from the article Biagioli V, Albanesi B, Belloni S, Piredda A, Caruso R. Living with cancer in the COVID-19 pandemic: An Italian survey on self-isolation at home. Eur J Cancer Care (Engl). 2021 Mar;30(2):e13385. doi: 10.1111/ecc.13385. Epub 2020 Dec 7. PMID: 33289205; PMCID: PMC7883078. Abstract Objective: To investigate the perception of self-isolation at home in patients with cancer during the lockdown period resulting from the COVID-19 outbreak in Italy. Methods: A cross-sectional descriptive study was conducted through an online survey of patients with cancer who were sheltering at home from 29th March to 3rd May 2020. Perception of self-isolation was assessed using the ISOLA scale, after evaluation of its psychometric properties. Content analysis was used to analyse two open-ended questions. Results: The participants were 195 adult patients with cancer (female = 76%; mean age = 50.3 ± 11.2; haematological malignancy = 51.3%). They reported moderate isolation-related suffering (M = 2.64 ± 0.81), problems in their relationships with others (M = 3.31 ± 1.13) and difficulties in their relationships with themselves (M = 3.14 ± 1.06). Patients who experienced significantly more social problems were older, had less education and were living without minor children. Overall, four main categories emerged from the qualitative content analysis: (1) lack of freedom and social life, (2) uncertainty and worries, (3) feeling supported and (4) dealing with isolation. Conclusion: Living with cancer in the COVID-19 pandemic was often perceived as an isolating experience, primarily in terms of detachment from loved ones.
DOI: 10.5281/zenodo.4643706
title: Dataset from Biagioli V, Albanesi B, Belloni S, Piredda A, Caruso R. Living with cancer in the COVID-19 pandemic: An Italian survey on self-isolation at home. Eur J Cancer Care (Engl). 2021 Mar;30(2):e13385. doi: 10.1111/ecc.13385. Epub 2020 Dec 7. PMID: 33289205; PMCID: PMC7883078.

description: Dataset from the article Biagioli V, Albanesi B, Belloni S, Piredda A, Caruso R. Living with cancer in the COVID-19 pandemic: An Italian survey on self-isolation at home. Eur J Cancer Care (Engl). 2021 Mar;30(2):e13385. doi: 10.1111/ecc.13385. Epub 2020 Dec 7. PMID: 33289205; PMCID: PMC7883078. Abstract Objective: To investigate the perception of self-isolation at home in patients with cancer during the lockdown period resulting from the COVID-19 outbreak in Italy. Methods: A cross-sectional descriptive study was conducted through an online survey of patients with cancer who were sheltering at home from 29th March to 3rd May 2020. Perception of self-isolation was assessed using the ISOLA scale, after evaluation of its psychometric properties. Content analysis was used to analyse two open-ended questions. Results: The participants were 195 adult patients with cancer (female = 76%; mean age = 50.3 ± 11.2; haematological malignancy = 51.3%). They reported moderate isolation-related suffering (M = 2.64 ± 0.81), problems in their relationships with others (M = 3.31 ± 1.13) and difficulties in their relationships with themselves (M = 3.14 ± 1.06). Patients who experienced significantly more social problems were older, had less education and were living without minor children. Overall, four main categories emerged from the qualitative content analysis: (1) lack of freedom and social life, (2) uncertainty and worries, (3) feeling supported and (4) dealing with isolation. Conclusion: Living with cancer in the COVID-19 pandemic was often perceived as an isolating experience, primarily in terms of detachment from loved ones.
DOI: 10.5281/zenodo.4643727
title: AuCoPro - Semantics

description: The AuCoPro-Semantics dataset serves for the automatic semantic analysis of compounds. It contains semantically annotated noun-noun compounds (NN) from Dutch and Afrikaans, split in two annotation rounds per language. The semantic annotation was performed with annotation guidelines based on those of Ó Séaghdha (2008). Another part of the dataset contains other nominal compounds (XN) in Dutch, that were annotated using a newly developed annotation scheme.
DOI: 10.5281/zenodo.4643726
title: AuCoPro - Semantics

description: The AuCoPro-Semantics dataset serves for the automatic semantic analysis of compounds. It contains semantically annotated noun-noun compounds (NN) from Dutch and Afrikaans, split in two annotation rounds per language. The semantic annotation was performed with annotation guidelines based on those of Ó Séaghdha (2008). Another part of the dataset contains other nominal compounds (XN) in Dutch, that were annotated using a newly developed annotation scheme.
DOI: 10.6084/m9.figshare.14317313
title: Data for Baud et al. (2021) JGR

description: CT, DVC, and mechanical data for Indiana limestone. Data for Baud et al. (2021; JGR).